Treatment options for patients with advanced neuroendocrine tumors (NETs) are limited. Here this group reports a single-arm, phase 2 trial assessing the safety and efficacy of cabozantinib and metronomic temozolomide in patients with advanced, progressive, well-differentiated NETs of gastroenteropancreatic, pulmonary or unknown origin.
- Mauro Cives
- Giuseppina Della Vittoria Scarpati
- Salvatore Tafuto